This article was originally published in The Gray Sheet
Completes patent license agreement with a subsidiary of The Laser Center under which Lasersight is granted an exclusive license to U.S. patent 5,630,810. The patent relates to a "treatment method for preventing formation of central islands," a problem associated with laser refractive surgery performed with broad beam laser systems used to ablate corneal tissue, the firm says. Lasersight agrees to pay TLC 20% of the aggregate net royalties it receives from licensing of the TLC patent
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.